Advance Search

Spring Meeting of the Young Researchers of SID, SIGG, SIIA, SIMI, SIPREC, SISA

Conference report - Spring Meeting 2025

Damiano D’Ardes
Institute of Clinica Medica, Department of Medicine and Aging Science, ‘G. D’Annunzio’ University of Chieti-Pescara, Italy
Vanessa Bianconi
SC Medicina Interna, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, Italy
Lorenzo Da Dalt
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy
Luca D’Onofrio
Department of Experimental Medicine, Sapienza University of Rome, Italy
Chiara Macchi
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy
Valeria Visco
Cardiovascular Research Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Italy
Martino Alfredo Cappelluti
San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
Ilaria Parrotta
IRCCS San Camillo Hospital, Venice, Italy
Carla Greco
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Italy
Leonardo Bencivenga
Department of Translational Medical Sciences, Federico II University, Naples, Italy
Rosa Curcio
Unit of Internal and Vascular Medicine, Azienda Ospedaliera Santa Maria, Terni, Italy
Mario Daidone
Internal Medicine and Stroke Care Ward, Policlinico P. Giaccone University Hospital, Palermo, Italy
Giovanna Gallo
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Cardiology Unit, Sant’Andrea University Hospital, Rome, Italy
Alessandro Maloberti
Department of Medicine, University of Milano-Bicocca, Milan, Italy; Cardiology 4, A.De Gasperis Cardio Center, ASST GOM Niguarda Ca' Granda, Milan, Italy
Giulia Rivasi
Division of Geriatric and Intensive Care Medicine, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Francesco Spannella
15 Internal Medicine and Geriatrics, IRCCS INRCA, Ancona, Italy; Department of Clinical and Molecular Sciences, University Politecnica Delle Marche, Ancona, Italy
Federica Piani
Department of Medical and Surgical Sciences, Cardiovascular Internal Medicine, University of Bologna, IRCCS Policlinico di Sant’Orsola, Bologna, Italy
Chiara Pavanello
Dipartimento di Scienze Farmacologiche e Biomolecolari Rodolfo Paoletti, Università degli Studi di Milano, Italy
Keywords:
Copyright and Licensing:

Copyright (c) 2025 European Atherosclerosis Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Abstract

The X Spring Meeting of Young Researchers, jointly organized by the Italian Society of Diabetology (SID), the Italian Society of Geriatrics and Gerontology (SIGG), the Italian Society of Arterial Hypertension (SIIA), the Italian Society of Internal Medicine (SIMI), the Italian Society of Cardiovascular Prevention (SIPREC), and the Italian Society for the Study of Atherosclerosis (SISA), took place in Rimini from April 6 to 8, 2025. This year’s event, titled “Spring MeeTENng – Between the PAST and FUTURE of Research, Spring is always PRESENT”, was coordinated by young researchers from the aforementioned scientific societies, with SIGG joining for the first time. The Congress featured five thematic sessions, each addressing timely issues in the prevention and treatment of cardiometabolic diseases, offering a retrospective and forward-looking perspective spanning the past decade.

The Congress was organized by “young researchers for young researchers” from the scientific societies listed first and operating in the cardiometabolic field. The Congress hosted five different sessions, each addressing crucial issues in the prevention and treatment of cardiometabolic diseases, with a perspective that spanned the past ten years and looked toward future developments. More than 100 young researchers actively participated in oral and poster sessions, presenting and exchanging ideas on their latest findings. In the following report, we outline the core themes explored in the Meeting’s lecture program.

PDF
PDF

Article Metrics Graph

Article Views | PDF Downloads
Chart Graph | Range Graph

References

  1. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674-86 https://doi.org/10.1038/nrendo.2017.99.
  2. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449-62 https://doi.org/10.1016/S0140-6736(18)31320-5.
  3. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313:37-44 https://doi.org/10.1001/jama.2014.16425.
  4. Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39:686-93 https://doi.org/10.2337/dc15-1990.
  5. Hero C, Rawshani A, Svensson AM, Franzen S, Eliasson B, Eeg-Olofsson K, et al. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. Diabetes Care. 2016;39:996-1003 https://doi.org/10.2337/dc15-2450.
  6. Guo J, Brooks MM, Muldoon MF, Naimi AI, Orchard TJ, Costacou T. Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes. Diabetes Care. 2019;42:1692-9 https://doi.org/10.2337/dc19-0480.
  7. Avogaro A, Azzolina D, Fadini GP, Baldi I. Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. J Endocrinol Invest. 2021;44:745-53 https://doi.org/10.1007/s40618-020-01368-5.
  8. Tecce N, Masulli M, Lupoli R, Della Pepa G, Bozzetto L, Palmisano L, et al. Evaluation of cardiovascular risk in adults with type 1 diabetes: poor concordance between the 2019 ESC risk classification and 10-year cardiovascular risk prediction according to the Steno Type 1 Risk Engine. Cardiovasc Diabetol. 2020;19:166 https://doi.org/10.1186/s12933-020-01137-x.
  9. Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab. 2019;21:2115-22 https://doi.org/10.1111/dom.13788.
  10. Nwokolo M, Hovorka R. The Artificial Pancreas and Type 1 Diabetes. J Clin Endocrinol Metab. 2023;108:1614-23 https://doi.org/10.1210/clinem/dgad068.
  11. Spronck B, Terentes-Printzios D, Avolio AP, Boutouyrie P, Guala A, Jeroncic A, et al. 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices. Hypertension. 2024;81:183-92 https://doi.org/10.1161/HYPERTENSIONAHA.123.21618.
  12. Bruno RM, Nilsson PM, Engstrom G, Wadstrom BN, Empana JP, Boutouyrie P, et al. Early and Supernormal Vascular Aging: Clinical Characteristics and Association With Incident Cardiovascular Events. Hypertension. 2020;76:1616-24 https://doi.org/10.1161/HYPERTENSIONAHA.120.14971.
  13. Badhwar S, Marais L, Khettab H, Poli F, Li Y, Segers P, et al. Clinical Validation of Carotid-Femoral Pulse Wave Velocity Measurement Using a Multi-Beam Laser Vibrometer: The CARDIS Study. Hypertension. 2024;81:1986-95 https://doi.org/10.1161/HYPERTENSIONAHA.124.22729.
  14. Greco MF, Rizzuto AS, Zara M, Cafora M, Favero C, Solazzo G, et al. PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells. Int J Mol Sci. 2022;23 https://doi.org/10.3390/ijms232113065.
  15. Macchi C, Greco MF, Favero C, Dioni L, Cantone L, Hoxha M, et al. Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. Front Cardiovasc Med. 2021;8:785250 https://doi.org/10.3389/fcvm.2021.785250.
  16. Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9:13 https://doi.org/10.1038/s41392-023-01690-3.
  17. Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025 https://doi.org/10.1016/j.jacc.2025.03.499.
  18. D'Erasmo L, Bini S, Casula M, Gazzotti M, Bertolini S, Calandra S, et al. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry. Eur J Prev Cardiol. 2024;31:1038-47 https://doi.org/10.1093/eurjpc/zwae036.
  19. Migliara A, Cappelluti MA, Giannese F, Valsoni S, Coglot A, Merelli I, et al. In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing. J Vis Exp. 2023 https://doi.org/10.3791/64403.
  20. Cappelluti MA, Mollica Poeta V, Valsoni S, Quarato P, Merlin S, Merelli I, et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature. 2024;627:416-23 https://doi.org/10.1038/s41586-024-07087-8.
  21. Bucciarelli V, Moscucci F, Dei Cas A, Coppi F, Angeli F, Pizzi C, et al. Maternal-fetal dyad beyond the phenomenology of pregnancy: from primordial cardiovascular prevention on out, do not miss this boat! Curr Probl Cardiol. 2024;49:102695 https://doi.org/10.1016/j.cpcardiol.2024.102695.
  22. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O, et al. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. Circ Res. 2022;130:652-72 https://doi.org/10.1161/CIRCRESAHA.121.319895.
  23. Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, et al. Promoting Risk Identification and Reduction of Cardiovascular Disease in Women Through Collaboration With Obstetricians and Gynecologists: A Presidential Advisory From the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation. 2018;137:e843-e52 https://doi.org/10.1161/CIR.0000000000000582.
  24. Khan SS, Brewer LC, Canobbio MM, Cipolla MJ, Grobman WA, Lewey J, et al. Optimizing Prepregnancy Cardiovascular Health to Improve Outcomes in Pregnant and Postpartum Individuals and Offspring: A Scientific Statement From the American Heart Association. Circulation. 2023;147:e76-e91 https://doi.org/10.1161/CIR.0000000000001124.
  25. WHO. https://population.un.org/wpp/. 2024.
  26. ISTAT. https://www.istat.it/statistiche-per-temi/popolazione/popolazione-e-famiglie/?dati.
  27. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394:1365-75 https://doi.org/10.1016/S0140-6736(19)31786-6.
  28. Arosio B, Picca A. The biological roots of the sex-frailty paradox. Exp Gerontol. 2024;198:112619 https://doi.org/10.1016/j.exger.2024.112619.
  29. Zeidan RS, McElroy T, Rathor L, Martenson MS, Lin Y, Mankowski RT. Sex differences in frailty among older adults. Exp Gerontol. 2023;184:112333 https://doi.org/10.1016/j.exger.2023.112333.
  30. Cesari M, Araujo de Carvalho I, Amuthavalli Thiyagarajan J, Cooper C, Martin FC, Reginster JY, et al. Evidence for the Domains Supporting the Construct of Intrinsic Capacity. J Gerontol A Biol Sci Med Sci. 2018;73:1653-60 https://doi.org/10.1093/gerona/gly011.
  31. Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024;20:261-77 https://doi.org/10.1038/s41574-023-00943-z.
  32. Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. Physiol Rev. 2019;99:427-511 https://doi.org/10.1152/physrev.00061.2017.
  33. Granic A, Suetterlin K, Shavlakadze T, Grounds MD, Sayer AA. Hallmarks of ageing in human skeletal muscle and implications for understanding the pathophysiology of sarcopenia in women and men. Clin Sci (Lond). 2023;137:1721-51 https://doi.org/10.1042/CS20230319.
  34. Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ. 2022;377:e068788 https://doi.org/10.1136/bmj-2021-068788.
  35. Bray GA, Kim KK, Wilding JPH, World Obesity F. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18:715-23 https://doi.org/10.1111/obr.12551.
  36. Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192:E875-E91 https://doi.org/10.1503/cmaj.191707.
  37. Kinlen D, Cody D, O'Shea D. Complications of obesity. QJM. 2018;111:437-43 https://doi.org/10.1093/qjmed/hcx152.
  38. Muller TD, Clemmensen C, Finan B, DiMarchi RD, Tschop MH. Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacol Rev. 2018;70:712-46 https://doi.org/10.1124/pr.117.014803.
  39. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49:433-51 https://doi.org/10.1038/s41366-024-01473-y.
  40. Boer GA, Holst JJ. Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches. Biology (Basel). 2020;9 https://doi.org/10.3390/biology9120473.
  41. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21 https://doi.org/10.1111/dom.13129.
  42. Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci. 2023;44:50-63 https://doi.org/10.1016/j.tips.2022.11.001.
  43. Brachs S, Soll D, Beer F, Huckauf N, Konkar A, Spranger J, et al. Hormonal regulation of human adipose tissue lipolysis: impact of adipose GIP system in overweight and obesity. Eur J Endocrinol. 2025;192:91-9 https://doi.org/10.1093/ejendo/lvae151.

Send mail to Author

Send Cancel

Custom technologies based on your needs

  • MongoDB
  • ElasticSearch
  • Redis
  • Solr
  • Memcached